The FDA Remestemcel-L submission for 2024 marks a significant moment in the world of biotechnology. As we await the outcomes of the review process, the potential for this therapy to transform the treatment landscape for steroid-refractory acute graft-versus-host disease is both exciting and promising.For patients, families, and healthcare providers, Remestemcel-L represents a beacon of hope, offering a new avenue for addressing a challenging condition. For the biotech industry, it highlights the ongoing advancements and the potential of innovative therapies to make a meaningful impact.
Thanks LED.
Aloha.
The FDA Remestemcel-L submission for 2024 marks a significant...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.78 |
Change
0.255(16.7%) |
Mkt cap ! $2.032B | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.83 | $1.71 | $27.76M | 15.59M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30000 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 48074 | 4 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |